Trichostatin A suppresses hearing loss by reducing oxidative stress and inflammation in an Alport syndrome model
PLOS ONE · 2025
DOI: 10.1371/journal.pone.0316033 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS ONE, 2025. Verfasst von Yoon Seok Nam und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Otolaryngology-Head and Neck Surgery, Chonnam National University Medical School and Chonnam National University Hospital, Gwangju, Rep…. Hauptthemen laut MEDLINE: Oxidative Stress, Nephritis, Hereditary, Hydroxamic Acids, Hearing Loss. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Chonnam National University Hospital Biomedical Research Institute grant, Basic Science Research Program through the National Research Foundation of Korea, funded by the Ministry of Education, Science and Technology, Commercialization’s Promotion Agency for R&D Outcomes (COMPA) grant funded by the Korean government.
Abstract (Originalsprache)
Alport syndrome (AS) is a genetic disorder marked by mutations in type IV collagen, leading to kidney glomerular dysfunction. AS also involves the cochlea, causing late-onset progressive hearing loss. Currently, there are no therapeutic drugs to protect hearing from AS. HDAC inhibitors (HDACis) are chemical compounds that block the activity of histone deacetylase and are known to exert diverse biologic effects. We investigated the effect of Trichostatin A (TSA), an HDACi, to assess its potential to inhibit hearing deterioration in AS. Col4a3 knockout (KO) mice were treated with TSA at 3 weeks of age, and hearing levels were measured using auditory brainstem response (ABR). The results demonstrate that TSA significantly protects the hearing of KO mice compared to the untreated group. The TSA-treated group exhibited a reduction in the levels of oxidative stress markers 4-Hydroxynonenal and 3-Nitrotyrosine, along with a decrease in inflammatory cytokines, in both the mouse cochlea and in vitro HEI-OC1 (House Ear Institute-Organ of Corti 1) cell and HEK (Human Embryonic Kidney)293T cells. AS demonstrated a thickening in the stria vascular vessels, a phenomenon that TSA attenuated. Col4α3 deficiency showed down-regulation of Hemeoxygenase-1 (HO-1), a key anti-inflammatory molecule. TSA treatment induced HO-1 signaling, which contributed to the inhibition of oxidative stress and inflammatory cytokines. These findings suggest that TSA represents a promising candidate molecule for mitigating the progression of hearing loss in AS.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Otolaryngology-Head and Neck Surgery, Chonnam National University Medical School and Chonnam National University Hospital, Gwangju, Republic of Korea.
- Department of Biomedical Science, College of Medicine, Chonnam National University Graduate School, BK21 PLUS Center for Creative Biomedical Scientists at Chonnam National University, Gwangju, Republic of Korea.
ORCID-Profile: Sungsu Lee, Hyong-Ho Cho
Förderung
- Chonnam National University Hospital Biomedical Research Institute grant
- Basic Science Research Program through the National Research Foundation of Korea, funded by the Ministry of Education, Science and Technology
- Commercialization’s Promotion Agency for R&D Outcomes (COMPA) grant funded by the Korean government
Zitieren
APA
Nam, Y. S., Gi, E. J., Ko, Y. S., Lee, S., & Cho, H. H. (2025). Trichostatin A suppresses hearing loss by reducing oxidative stress and inflammation in an Alport syndrome model. PLOS ONE. https://doi.org/10.1371/journal.pone.0316033
Vancouver
Nam YS, Gi EJ, Ko YS, Lee S, Cho HH. Trichostatin A suppresses hearing loss by reducing oxidative stress and inflammation in an Alport syndrome model. PLOS ONE. 2025. doi:10.1371/journal.pone.0316033
BibTeX
@article{Nam2025,
author = {Nam, Yoon Seok and Gi, Eun-Ji and Ko, Yoo-Seung and Lee, Sungsu and Cho, Hyong-Ho},
title = {Trichostatin A suppresses hearing loss by reducing oxidative stress and inflammation in an Alport syndrome model},
journal = {PLOS ONE},
year = {2025},
doi = {10.1371/journal.pone.0316033}
}
EUVIMED